Skip to main content

Table 3 Predicted cost-effectiveness of Wolbachia at the end of the programme. Accelerated and sequenced programmes correspond to completing roll out in 3 and 10 years, respectively. Only eligible areas (at least 1000 people per km2) receive treatment. All costs are in present value 2018 US dollars. All costs and benefits are discounted at a rate of 3% per annum. Net costs include cost offsets for medical and societal benefits from averted cases. Figures in brackets represent 95% uncertainty intervals

From: The cost-effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: a modelling study

 Committed areaScale-up scenario
Yogyakarta CityRemaining Yogyakarta SARJakartaBali
  Accelerated introduction 
Gross $/DALY averted$ 1831 (892–4522)$ 2133 (1048–4953)$ 1566 (857–3244)$ 2996 (1599–6778)
Net $/DALY averted (including averted medical and societal costs)$ − 543 (− 1419–1976)$ - 242 (− 1275–2438)$ − 839 (− 1500–731)$ 671 (− 719–4219)
  Sequenced introduction 
Gross $/DALY averted$ 1519 (737–3732)$ 2168 (1064–5042)$ 1111 (611–2307)$ 2366 (1264–5379)
Net $/DALY averted (including health sector and societal costs)$ − 862 (− 1572–1185)$ − 210 (− 1258–2528)$ − 1280 (− 1772–− 207)$ 64 (− 1050–2834)